直接PCI中早期经冠脉给予地尔硫卓预防无复流的效果  

Clinical study on prevention of no-reflow by early administration of intracoronary diltiazem through coronary artery during direct PCI

作　　者：史东[1] 韩丽[1] 张峰[1] 任自文[1] 

机构地区：[1]泰达国际心血管病医院,天津市300457

出　　处：《实用医学杂志》2014年第23期3832-3834,共3页The Journal of Practical Medicine

摘　　要：目的:评估冠脉内早期给予地尔硫卓对急性心肌梗死直接经皮冠状动脉介入治疗(PCI)无复流的预防作用。方法:选择我院心内科2010年6月至2013年11月行急诊PCI的134例急性心肌梗死患者,治疗组60例,在直接PCI中早期预防性冠脉内给予地尔硫卓。对照组74例,未给予地尔硫卓。排除术前持续严重低血压以及持续三度房室传导阻滞患者。冠脉造影时以及PCI完成即刻对梗死相关血管的血流情况进行评估。结果:两组患者具有相似的基线特征。PCI即刻评价无复流发生与否(P=0.04)方面及c TFC(P=0.00)方面两组比较差异具有统计学意义。结论:急性心肌梗死直接PCI早期冠脉内给予地尔硫卓可以预防无复流的发生。Objective To evaluate the effects of the administration of intracoronary diltiazem before the occurrence of no-reflow during direct PCI. Mtthods One hundred and thirty four AMI patients hospitalized from June 2001 to November 2003 were selected as research objects. 60 patients with AMI received intracoronary diltiazem before the occurrence of no-reflow during direct PCI. 74 AMI patients did not receive intracoronary diltiazem and were enrolled as control subjects. Patients with refractory low blood pressure and complete atrioventricular block before PCI were excluded. Thrombolysis in Myocardial Infarction （TIMI） flow grade, corrected TIMI frame count （CTFC） were assessed during angiography, before and after PCI. Results The two groups had similar baseline. There were significant difference in post-PCI no reflow assessment （P = 0.04） and CTFC （P = 0.00）. Conclusion Early administration of intracoronary diltiazem during direct PCI reduces the no reflow occurrence.

关 键 词：冠状动脉成形术 冠脉内给药 地尔硫卓 心肌梗死 无复流 

分 类 号：R542.22[医药卫生—心血管疾病]